Journal article
Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models
V Liapis, W Tieu, NL Wittwer, T Gargett, A Evdokiou, P Takhar, SE Rudd, PS Donnelly, MP Brown, AH Staudacher
Molecular Imaging and Biology | Published : 2021
Abstract
Purpose: Early detection of tumor treatment responses represents an unmet clinical need with no approved noninvasive methods. DAB4, or its chimeric derivative, chDAB4 (APOMAB®) is an antibody that targets the Lupus associated antigen (La/SSB). La/SSB is over-expressed in malignancy and selectively targeted by chDAB4 in cancer cells dying from DNA-damaging treatment. Therefore, chDAB4 is a unique diagnostic tool that detects dead cancer cells and thus could distinguish between treatment responsive and nonresponsive patients. Procedures: In clinically relevant tumor models, mice bearing subcutaneous xenografts of human ovarian or lung cancer cell lines or intraperitoneal ovarian cancer xenogra..
View full abstractGrants
Awarded by South Australian Health and Medical Research Institute
Funding Acknowledgements
The authors acknowledge the facilities and technical assistance provided via Dr Marianne Keller of the National Imaging Facility, a National Collaborative Research Infrastructure Strategy (NCRIS) initiative and the staff in the Bioresources department of the South Australian Health and Medical Research Institute (SAHMRI). We acknowledge Mass Spectrometry and Proteomics Facility (MSPF) at Bio21 institute, University of Melbourne for the use of mass spectrometer and HPLC systems. We thank Dr Michelle Nottage and Mr Dale Searcy of Dr Jones & Partners Medical Imaging at the Clinical Research Imaging Centre of SAHMRI for their assistance with preparation of PET maximum intensity projections. This study was funded by AusHealth Pty Ltd, Adelaide, National Health and Medical Research Council, Australia (Project Grant ID 1126304), Royal Adelaide Hospital Clinical Project Grant (Project Grant ID 12872) and the Ray and Shirl Norman Cancer Research Trust.